Propanc Health Group Corporation (OTCQB: PPCH), a research and development company, announced today that it has filed a third patent regarding the use of its lead product, PRP, as a method to treat cancer by targeting cancer stem cell eradication, while sparing normal stem cells.
Through the company's research partners at the Universities of Jaén and Granada in Spain, experiments were conducted using isolated CSCs from patients, comparing the behavior of these cells pre and post treatment with PRP by examining the genetic pathways that control these cells.
"After conducting these experiments, I conclude that PRP is quite dramatically suppressing the metastatic potential of CSCs by regulating the EMT process,” said Dr Macarena Perán, Lecturer and Laboratory Manager, at the University of Jaén. This is quite relevant, because in CSCs, the EMT machinery is working very hard to maintain their metastatic potential compared with 'normal' cancer cells." "Furthermore, the EMT seems to be suppressed via several different ways.Any one of these facts, per se, will be enough to justify developing a new compound, and we have identified three pathways, so the results are very encouraging."
Propanc Targeting Tumor Types with Few Treatment Options
Focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancers, the emerging healthcare company, through scientific research undertaken over the last 15 years and the clinical experience from treating patients in the UK and Australia, has provided evidence that PRP may be an effective treatment against cancer. Targeting tumor types where few treatment options exist, Propanc is now seeking worldwide regulatory approval in several therapeutic indications for their lead product.
"I am delighted with the results achieved through our research partners, and look forward to further elucidating the molecular target by which the proenzymes exert their effects,” said James Nathanielsz, CEO of Propanc.“Not only have we now shown that PRP halts a fundamental mechanism by which cancer grows and spreads in order to reduce the risk of relapse, but we can now turn our attention towards developing new compounds which further enhance these clinical effects. As a result of this hard work and persistence, we have been able to identify a third invention in the field, which strengthens our intellectual property portfolio and increases the value of our company.”
Propanc has reported a number of operational highlights in recent months, including the Initiation of animal safety toxicology studies for PRP. Furthermore, earlier this month, the company received an additional $525,000 from an institutional investor.
According to the World Health Organization, the number of new cancer cases is expected to rise by about 70% over the next two decades. Propanc’s continued developments and promising research results have the capability to equip the medical field with effective cancer treatments to fight a fatal disease on the rise. "This significant step forward in our scientific understanding will provide a great deal of confidence as we look towards initiating patient trials later this year," said Dr Julian Kenyon, Propanc's Chief Scientific Officer.
For more information about Propanc Health Group, visit www.propanc.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of
1933 and in the interest of full disclosure, we call the reader's
attention to the fact that Equities.com, Inc. may be compensated by the
companies profiled in the Spotlight Companies section. The purpose of
these profiles is to provide awareness of these companies to investors
in the micro, small-cap and growth equity community and should not in
any way come across as a recommendation to buy, sell or hold these
securities. Equities.com is not a registered broker, broker dealer,
investment advisor, analyst, investment banker or underwriter. All
profiles are based on information that is available to the public. The
information contained herein should not be considered to be
all-inclusive and is not guaranteed by Equities.com to be free from
misstatement or errors. Readers are reminded to do their own due
diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer